Study of visual and anatomical outcomes of second year aflibercept in good visual acuity baseline of wet age-related macular degeneratio
- Conditions
- Age-related macular degeneration
- Registration Number
- JPRN-UMIN000016598
- Lead Sponsor
- Department of Ophthalmology, Jichi Medical University
- Brief Summary
Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study. Shinichi Sakamoto, Hidenori Takahashi, Yuji Inoue, Yusuke Arai, Satoru Inoda, Natsuko Kakinuma, Yujiro Fujino, Tatsuro Tanabe, Hidetoshi Kawashima, Yasuo Yanagi Clinical ophthalmology (Auckland, N.Z.) 12 1137-1147 2018
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 39
Not provided
1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas 2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area) 3) Prior treatment with anti-VEGF drug, photodynamic therapy 4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months) 5) Active intraocular inflammation 6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7) Patient who the doctor in charge judges are ineligible for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of best-collected visual acuity and proportion of improved, maintained and deteriorated visual acuity at month 24 from 12 after initial injection of aflibercept
- Secondary Outcome Measures
Name Time Method Change of (best-collected visual acuity) BCVA, central macular thickness, subretinal fluid and polyps regression